Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLASCO Taiwan CoROCO:6662 -0.17%77 Net Margin % is 24.57% as of Dec. 2025, which is 39% above its 10-year median of 17.70. GuruFocus rates ROCO:6662 with a GF Score™ of 77/100 and a GF Value™ of NT$34.19 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, BioLASCO Taiwan Co ranks better than 85.03% on this metric.
The historical rank and industry rank for BioLASCO Taiwan Co's Net Margin % or its related term are showing as below:
ROCO:6662'
s Net Margin % Range Over the Past 10 Years
Min: 15.05 Med: 17.7 Max: 21.01
Current: 16.15
ROCO:6662's Net Margin % is ranked better than 85.03% of 942
companies
in the Biotechnology industry
Industry Median: -88.815
vs ROCO:6662: 16.15
BioLASCO Taiwan Co (ROCO:6662) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BioLASCO Taiwan Co Net Margin % Related Terms
BioLASCO Taiwan Co Net Margin % Historical Data
* Premium members only.
The historical data trend for BioLASCO Taiwan Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6662 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, BioLASCO Taiwan Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLASCO Taiwan Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLASCO Taiwan Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where BioLASCO Taiwan Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLASCO Taiwan Co (ROCO:6662) has a Net Margin % of 24.57% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on BioLASCO Taiwan Co and its competitors. This is 39% above median its historical median of 17.70. Over the past decade, BioLASCO Taiwan Co's Net Margin % has ranged from 15.05 to 21.01. According to the industry distribution chart, BioLASCO Taiwan Co ranks #141 out of 942 companies in the Biotechnology industry, placing it in the top 15%.
Is BioLASCO Taiwan Co's Net Margin % too high?
BioLASCO Taiwan Co's current Net Margin % of 24.57% is 39% above median its 10-year median of 17.70. Over the past 10 years, this metric has ranged from a low of 15.05 to a high of 21.01. Based on the distribution chart, BioLASCO Taiwan Co ranks #141 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioLASCO Taiwan Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioLASCO Taiwan Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLASCO Taiwan Co ranks #141 out of 942 companies for Net Margin %. This places BioLASCO Taiwan Co in the top 15% of its industry — outperforming the majority of peers. Historically, BioLASCO Taiwan Co's own Net Margin % has ranged from 15.05 to 21.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BioLASCO Taiwan Co and its competitors. BioLASCO Taiwan Co's current Net Margin % is 24.57%, which is 39% above median its own 10-year median of 17.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLASCO Taiwan Co stock overvalued right now?
Based on GuruFocus' analysis, BioLASCO Taiwan Co (ROCO:6662) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$34.19, compared to a current price of NT$29.70 — trading 13.1% below its estimated fair value. The current Net Margin % is 24.57%, which is 39% above median its 10-year median of 17.70. BioLASCO Taiwan Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BioLASCO Taiwan Co (ROCO:6662), the current Net Margin % is 24.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLASCO Taiwan Co (ROCO:6662) Overvalued in 2026?
Based on GuruFocus' analysis, BioLASCO Taiwan Co stock appears to be undervalued.
The current stock price of NT$29.70 is trading 13.1% below its estimated GF Value™ of NT$34.19.
GuruFocus considers BioLASCO Taiwan Co to be Modestly Undervalued.
Key valuation signals for ROCO:6662:
Net Margin %: 24.57% (39% above median its 10-year median of 17.70)
GF Value™: NT$34.19 vs. price of NT$29.70 (13.1% below fair value)
No single metric tells the full story. See the ROCO:6662 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLASCO Taiwan Co Ltd is a biological experimental development company. The company has produced strains of laboratory rats and mice, including outbreed stocks, inbreed strains, and immunedeficient models. It offers reagent kits and equipment which include Allentown, a Biomedical data system, and PLAS LABS.
77GF Score
Get the complete analysis for ROCO:6662
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6662 has been successfully added to your 
